Residual cardiovascular (CV) risk persists despite achieving low-density lipoprotein cholesterol (LDL-C) targets with lipid-lowering therapy, indicating the role of other lipid parameters. Robust evidence has shown that non-high-density lipoprotein cholesterol (non-HDL-C) confers better estimation of atherosclerotic cardiovascular disease (ASCVD) risk than LDL-C and is increasingly recognized as a treatment target in atherogenic dyslipidemia. While global guidelines have incorporated non-HDL-C as a primary/coprimary lipid target, most Asia-Pacific (APAC) guidelines region still consider it secondary to LDL-C. To address this gap, we developed a consensus document with evidence-based recommendations using modified Delphi method involving 11 experts across 10 APAC countries. This offers practical guidance on adopting non-HDL-C as a lipid target, including add-on therapies to statins for reducing non-HDL-C and CV risk in atherogenic dyslipidemia. Acknowledging regional variations in lipid targets, this document does not override local APAC guidelines, but rather encourages physicians to manage non-HDL-C in alignment with those guidelines .
JACC: Asia Editor-in-Chief
Jian’an Wang, MD, PhD, FACC
CME Editor
Kenneth A. Ellenbogen, MD
Author
Barbara Wiggins, PharmD, FACC
Important Dates
Date of Release: April 7, 2026
Term of Approval/Date of CME/MOC Expiration: April 6, 2027